Neonc Technologies (NASDAQ:NTHI) Stock: Insider Amir Heshmatpour Purchases 30,000 Shares

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour acquired 30,000 shares of Neonc Technologies stock in a transaction that occurred on Thursday, November 5th. The shares were bought at an average price of $3.17 per share, with a total value of $95,100.00. Following the transaction, the chief executive officer directly owned 3,213,000 shares in the company, valued at approximately $10,185,210. This trade represents a 0.94% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Neonc Technologies Stock Performance

Shares of NTHI opened at $4.37 on Wednesday. The stock has a fifty day moving average price of $3.30 and a 200 day moving average price of $5.34. Neonc Technologies Holdings, Inc. has a 12 month low of $2.50 and a 12 month high of $12.00.

Neonc Technologies (NASDAQ:NTHI) last issued its earnings results on Thursday, November 5th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.25) by ($0.03).

Institutional Trading of Neonc Technologies

Several hedge funds have recently added to or reduced their stakes in the business. Bank of America Corp DE bought a new stake in Neonc Technologies during the 2nd quarter valued at $1,017,000. BlackRock Inc. bought a new position in shares of Neonc Technologies in the second quarter worth $815,000. Westmount Partners LLC grew its stake in shares of Neonc Technologies by 355.2% in the second quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares in the last quarter. Finally, Global Retirement Partners LLC bought a new position in shares of Neonc Technologies in the second quarter worth $126,000.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on NTHI shares. BTIG Research reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Neonc Technologies in a report on Tuesday, September 8th. Weiss Ratings lowered shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, October 21st. Roth Capital initiated coverage on shares of Neonc Technologies in a research note on Thursday, September 24th. They set a “buy” rating for the company. Wall Street Zen upgraded shares of Neonc Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. Finally, Zacks Research upgraded shares of Neonc Technologies from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 5th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

About Neonc Technologies

NeOnc Technologies Holdings, Inc. is a biotechnology company developing treatments for brain tumors and other central nervous system cancers. Its research focuses on approaches intended to deliver therapies to the brain, where the blood-brain barrier can limit the effectiveness of conventional treatments. The company’s pipeline includes NEO100, a formulation of perillyl alcohol designed for intranasal delivery, and NEO212, a compound combining perillyl alcohol with temozolomide. These candidates are being developed for potential use in brain cancer treatment.